UNITHER
Acquired by
ARDIAN
UNITHER acquired by ARDIAN
Target
UNITHER
Acquirer
ARDIAN
Context
Ardian, an independent private investment firm, has entered into exclusive negotiations to acquire a majority stake in Unither Pharmaceuticals, a global leader in the Contract Development and Manufacturing Organization (CDMO) sector. Ardian submitted a firm offer to Equistone, which leads a consortium of sellers including historical shareholders Parquest Capital and CM-CIC Investissement.
The transaction values UNITHER at an EV/Revenue multiple of LOGIN.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Global leader in sterile unit-dose manufacturing using Blow-Fill-Seal (BFS) technology. The group provides contract development and manufacturing services for pharmaceutical companies, specializing in ophthalmology, respiratory diseases, and saline solutions.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with UNITHER
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 10/2022 | IK PARTNERS | UNITHER | FRANCE | CDMO | Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions. The consortium is acquiring the majority stake from Ardian, following a successful five-year partnership. |
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.